A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19
NCT06039163
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
COVID-19
Interventions
DRUG:
HH-120
DRUG:
placebo
Sponsor
Huahui Health